| 2025-05-15 |
详情>>
股本变动：
变动后总股本3116.01万股
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-9.37美元,归母净利润-1089.1万美元,同比去年增长-35.68%
|
| 2025-05-01 |
复牌提示：
2025-04-30 19:50:00 停牌，复牌日期 2025-05-01 09:00:00
|
| 2025-05-01 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-3.34美元,归母净利润-2679.72万美元,同比去年增长-93.98%
|
| 2025-03-18 |
股东大会：
将于2025-04-10召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”) underlying the Series A warrants (the “Series A Warrants”) and Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Series Warrants”), including by operation of certain anti-dilution provisions contained therein, issued by us in a public offering transaction (the “Offering”) on February 19, 2025 (including an aggregate of approximately 1,064,846,416.38 shares of Common Stock issuable upon exercise of the Series Warrants, which consists of (i) an aggregate of approximately 81,911,262.80 shares of Common Stock issuable upon exercise of 40,000,000 Series A Warrants issued in the Offering (assuming the full exercise of the Series A Warrants at an exercise price equal to the floor price of $0.0586) and (ii) an aggregate of approximately 982,935,153.58 shares of Common Stock issuable upon exercise of 40,000,000 Series B Warrants issued in the Offering (assuming (x) the full exercise of the Series B Warrants at an exercise price equal to the floor price of $0.0586 and (y) all the Series B Warrants are exercised on the “zero exercise price” basis) (“Proposal 1” or, the “Issuance Proposal”);
2.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”) to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-250 to 1-for-500, with such ratio to be determined by the board of directors (the “Board”) of the Company in its discretion and included in a public announcement (“Proposal 2” or, the “Reverse Stock Split Proposal”);
3.To approve the Third Amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended, to increase the total number of shares of the Company’s Common Stock authorized for issuance under such plan by 1,000,000,000, to a total of 1,002,760,000 shares of Common Stock (“Proposal 3” or, the “Plan Amendment Proposal”);
4.To approve an amendment to the Charter to increase the number of our authorized shares of Common Stock from 250,000,000 shares to 7,000,000,000 shares and to make a corresponding change to the number of authorized shares of capital stock (“Proposal 4” or, the “Share Increase Proposal”);
5.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of any one or more of the foregoing proposals (“Proposal 5” or, the “Adjournment Proposal”).
|
| 2025-02-19 |
详情>>
内部人交易：
WALKER WAYNE REMELL等共交易5笔
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.18美元,归母净利润-1600.86万美元,同比去年增长-81.49%
|
| 2024-10-25 |
股东大会：
将于2024-11-20召开股东大会
会议内容 ▼▲
- 1.To elect the three directors named in the Proxy Statement to the Board of Directors (the “Board”) of the Company to serve one-year terms expiring in 2025 (“Proposal 1”);
2.To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 2”);
3.To approve, on an advisory basis, the compensation paid to our named executive officers (“Proposal 3”);
4.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1-for-2 to 1-for-25, with such ratio to be determined by the Board in its discretion and included in a public announcement (“Proposal 4”);
5.To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of any one or more of the foregoing proposals (“Proposal 5”);
6.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-1.77美元,归母净利润-1076.19万美元,同比去年增长-173.71%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-1.69美元,归母净利润-802.69万美元,同比去年增长-479.5%
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-6.35美元,归母净利润-1381.44万美元,同比去年增长31.06%
|
| 2023-11-30 |
股东大会：
将于2023-12-29召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to the Board of Directors (the “Board”) of the Company to serve one-year terms expiring in 2024;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation paid to our named executive officers;
4.To approve, on an advisory basis, the compensation paid to our named executive officers;
|
| 2023-11-15 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-4.18美元,归母净利润-882.06万美元,同比去年增长44.23%
|
| 2023-08-25 |
股东大会：
将于2023-09-14召开股东大会
会议内容 ▼▲
- 1.To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying shares of convertible preferred stock and warrants issued by us in a private placement in July 2023, in an amount equal to or in excess of 20% of our common stock outstanding before the issuance of such convertible preferred stock and warrants (including any amortization payments made to the holders of convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions applicable to such convertible preferred stock and warrants in accordance with their terms) (the “Issuance Proposal”);
2.To approve a proposed amendment to the Amended and Restated Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan to increase the aggregate number of shares available for the grant of awards by 2,500,000 shares, to a total of 2,760,000 shares of common stock (the “Incentive Plan Amendment Proposal”);
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 150,000,000 to 250,000,000 and to make a corresponding change to the number of authorized shares of capital stock (the “Share Increase Proposal”);
4.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Issuance Proposal, the Incentive Plan Amendment Proposal or the Share Increase Proposal.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-1.87美元,归母净利润-393.18万美元,同比去年增长-97.98%
|
| 2023-05-15 |
详情>>
业绩披露：
2023年一季报每股收益-0.66美元,归母净利润-138.51万美元,同比去年增长-695.04%
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-9.68美元,归母净利润-2003.76万美元,同比去年增长-122.97%
|
| 2022-12-01 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-10-12 |
股东大会：
将于2022-11-29召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the Proxy Statement to the Board of Directors (the “Board”) of the Company to serve one-year terms expiring in 2023;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1-for-4 to 1-for-10, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”);
3.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To approve, on an advisory basis, the compensation paid to our named executive officers;
5.To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal (the “Adjournment Proposal”);
6.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2021-11-22 |
股东大会：
将于2021-12-22召开股东大会
会议内容 ▼▲
- 1.To elect the five directors named in the accompanying Proxy Statement to the Board of Directors of the Company to serve one-year terms expiring in 2022;
2.To approve a proposed amendment to the Petros Pharmaceuticals, Inc. 2020 Omnibus Incentive Compensation Plan, as amended, to increase the aggregate number of shares available for the grant of awards by 1,521,654 shares, to a total of 2,600,000 shares;
3.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To approve, on an advisory basis, the compensation paid to our named executive officers;
5.To approve, on an advisory basis, of the frequency of future advisory votes on the compensation to be paid to our named executive officers;
6.To transact such other business that is properly presented at the Annual Meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|